BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Citi
Julphar
Mallinckrodt
Moodys
Covington
Deloitte
Medtronic
Cantor Fitzgerald
UBS

Generated: January 19, 2018

DrugPatentWatch Database Preview

Pfizer Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?

PFIZER has one hundred and fifty-four approved drugs.

There are sixty-two US patents protecting PFIZER drugs and there have been two Paragraph IV challenges on PFIZER drugs in the past three years. There is one tentative approval on PFIZER drugs.

There are one thousand eight hundred and seventy patent family members on PFIZER drugs in seventy-nine countries and one hundred and fifty-eight supplementary protection certificates in fourteen countries.

Summary for Pfizer
International Patents:1870
US Patents:62
Tradenames:121
Ingredients:107
NDAs:154
Drug Master File Entries: 3

Drugs and US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer CAVERJECT alprostadil INJECTABLE;INJECTION 020755-002 Oct 1, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990-001 Dec 7, 1999 AA RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer NAVANE thiothixene CAPSULE;ORAL 016584-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer DIFLUCAN fluconazole TABLET;ORAL 019949-004 Jun 30, 1994 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer REVATIO sildenafil citrate TABLET;ORAL 021845-001 Jun 3, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-002 Dec 4, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-002 Dec 4, 2015 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer SINEQUAN doxepin hydrochloride CAPSULE;ORAL 016798-005 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Inc IBRANCE palbociclib CAPSULE;ORAL 207103-003 Feb 3, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Pfizer Inc IBRANCE palbociclib CAPSULE;ORAL 207103-002 Feb 3, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-009 Jul 29, 2004 ➤ Subscribe ➤ Subscribe
Pfizer TROVAN trovafloxacin mesylate TABLET;ORAL 020759-001 Dec 18, 1997 ➤ Subscribe ➤ Subscribe
Pfizer NORVASC amlodipine besylate TABLET;ORAL 019787-002 Jul 31, 1992 ➤ Subscribe ➤ Subscribe
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-003 Aug 10, 1999 ➤ Subscribe ➤ Subscribe
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-002 Apr 26, 1994 ➤ Subscribe ➤ Subscribe
Pfizer Inc CAMPTOSAR irinotecan hydrochloride INJECTABLE;INJECTION 020571-001 Jun 14, 1996 ➤ Subscribe ➤ Subscribe
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-001 Jan 27, 2006 ➤ Subscribe ➤ Subscribe
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-002 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-004 Jan 30, 1998 ➤ Subscribe ➤ Subscribe
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 11/7/2016
➤ Subscribe Capsules 200 mg/38 mg ➤ Subscribe 2/16/2016
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 5/1/2014
➤ Subscribe Extended-release Tablets 4 mg and 8 mg ➤ Subscribe 10/31/2012
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 12/29/2011
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 6/17/2011
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 5/10/2010
➤ Subscribe Tablets 20 mg and 40 mg ➤ Subscribe 3/29/2010
➤ Subscribe Tablets 2.5 mg/40 mg ➤ Subscribe 9/17/2009
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 4/7/2009
➤ Subscribe Tablets 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg ➤ Subscribe 12/29/2006
➤ Subscribe Tablets 150 mg and 200 mg ➤ Subscribe 11/9/2005
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 10/19/2005
➤ Subscribe Capsules 5 mg and 10 mg ➤ Subscribe 6/21/2005
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2/7/2005
➤ Subscribe Capsules 200 mg/30 mg ➤ Subscribe 12/27/2004
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 11/19/2004
➤ Subscribe Tablets 100 mg ➤ Subscribe 10/25/2004
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 7/26/2004
Premature patent expirations for PFIZER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Pfizer

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,180,100 Methylphenidate extended release chewable tablet ➤ Subscribe
9,364,541 Pharmaceutical compositions comprising Fesoterodine ➤ Subscribe
6,713,464 Derivatives of 3,3-diphenylpropylamines ➤ Subscribe
6,514,496 Dispersible antibody compositions and methods for their preparation and use ➤ Subscribe
8,449,876 Human lysosomal proteins from plant cell culture ➤ Subscribe
6,681,767 Method and device for delivering aerosolized medicaments ➤ Subscribe
7,951,557 Human lysosomal proteins from plant cell culture ➤ Subscribe
7,205,300 Aryl fused azapolycyclic compounds ➤ Subscribe
6,592,904 Dispersible macromolecule compositions and methods for their preparation and use ➤ Subscribe
6,380,226 Salts of an anti-migraine indole derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Pfizer Drugs

Supplementary Protection Certificates for Pfizer Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2004005 Lithuania ➤ Subscribe PRODUCT NAME: INSULIN DETEMIR
2/2005 Austria ➤ Subscribe PRODUCT NAME: INSULIN GLULISINE
80045 Netherlands ➤ Subscribe PRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204
60026 Netherlands ➤ Subscribe PRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
00002 Netherlands ➤ Subscribe PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129
00375 Netherlands ➤ Subscribe PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
C/GB99/024 United Kingdom ➤ Subscribe PRODUCT NAME: N-(3-(3-CYANOPYRAZOLO(1,5-A)PYRIMIDIN-7-YL)PHENYL)-N-ETHYLACETAMIDE (ZALEPLON); REGISTERED: UK EU/1/99/099/001 19990312; UK EU/1/99/099/002 19990312; UK EU/1/99/099/003 19990312; UK EU/1/99/099/004 19990312; UK EU/1/99/099/005 19990312; UK EU/1/99/099/006 19990312; UK EU/1/99/102/001 19990312; UK EU/1/99/102/002 19990312; UK EU/1/99/102/003 19990312; UK EU/1/99/102/004 19990312; UK EU/1/99/102/005 19990312; UK EU/1/99/102/006 19990312
13/34 Ireland ➤ Subscribe PRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
0880 Netherlands ➤ Subscribe PRODUCT NAME: SNELWERKENDE INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
0164 Netherlands ➤ Subscribe 300164, 20130518, EXPIRES: 20180517
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
US Army
Colorcon
McKesson
Farmers Insurance
Fish and Richardson
Deloitte
Accenture
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot